Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams & Wilkins
Access Rights
info:eu-repo/semantics/closedAccess
DOI
Abstract
Description
Keywords
Journal or Series
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
WoS Q Value
Scopus Q Value
Volume
41
Issue
16
Citation
Özcan, M., Lee, S. T., Mensah, F., Modi, D., Fossa, A., Kim, W. S. ... Lavie, D. (2023). Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 41(16). Chicago, IL, 02-06 June, 2023.
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
info:eu-repo/semantics/closedAccess
